Tekwani Babu L, Walker Larry A
National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University, MS 38677, USA.
Comb Chem High Throughput Screen. 2005 Feb;8(1):63-79. doi: 10.2174/1386207053328101.
Clinical manifestations of malaria primarily result from proliferation of the parasite within the hosts' erythrocytes. During this process, hemoglobin is utilized as the predominant source of nutrition. The malaria parasite digests hemoglobin within the digestive vacuole through a sequential metabolic process involving multiple proteases. Massive degradation of hemoglobin generates large amount of toxic heme. Malaria parasite, however, has evolved a distinct mechanism for detoxification of heme through its conversion into an insoluble crystalline pigment, known as hemozoin. Hemozoin is identical to beta-hematin, which is constituted of cyclic heme dimers arranged in an ordered crystalline structure through intermolecular hydrogen bonding. The exact mechanism of biogenesis of hemozoin in malaria is still obscure and is the subject of intense debate. Hemozoin synthesis is an indispensable process for the parasite and is the target for action of several known antimalarials. The pathway has therefore attracted significant interest for new antimalarial drug discovery research. Formation of beta-hematin may be achieved in vitro under specific chemical and physiochemical conditions through a biocrystallization process. Based on these methods several experimental approaches have been described for the assay of formation of beta-hematin in vitro and screening of compounds as inhibitors of hemozoin synthesis. These assays are primarily based on differential solubility and spectral characteristics of monomeric heme and beta-hematin. Different factors viz., the malaria parasite lysate, lipids extracts, preformed beta-hematin, malarial histidine rich protein II and some unsaturated lipids have been employed for promoting beta-hematin formation in these assays. The assays based on spectrophotometric quantification of beta-hematin or incorporation of (14)C-heme yield reproducible results and have been applied to high throughput screening. Several novel antimalarial pharmacophores have been discovered through these assays.
疟疾的临床表现主要源于寄生虫在宿主红细胞内的增殖。在此过程中,血红蛋白被用作主要营养来源。疟原虫通过涉及多种蛋白酶的连续代谢过程在消化泡内消化血红蛋白。血红蛋白的大量降解产生大量有毒血红素。然而,疟原虫已经进化出一种独特的机制,通过将血红素转化为一种不溶性结晶色素(即疟色素)来进行血红素解毒。疟色素与β-血红素相同,β-血红素由环状血红素二聚体通过分子间氢键排列成有序的晶体结构组成。疟原虫中疟色素生物合成的确切机制仍然不清楚,是激烈争论的主题。疟色素合成是寄生虫不可或缺的过程,也是几种已知抗疟药的作用靶点。因此,该途径在新抗疟药物发现研究中引起了极大的兴趣。在特定的化学和物理化学条件下,通过生物结晶过程可以在体外实现β-血红素的形成。基于这些方法,已经描述了几种体外测定β-血红素形成和筛选作为疟色素合成抑制剂的化合物的实验方法。这些测定主要基于单体血红素和β-血红素的不同溶解度和光谱特征。在这些测定中,已经使用了不同的因素,即疟原虫裂解物、脂质提取物、预先形成的β-血红素、富含组氨酸的疟疾蛋白II和一些不饱和脂质来促进β-血红素的形成。基于β-血红素的分光光度法定量或(14)C-血红素掺入的测定产生可重复的结果,并已应用于高通量筛选。通过这些测定发现了几种新型抗疟药效团。